Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

139.03 +0.04 (+0.03%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9

...

72 73 Next >

Q4 Earnings Highs And Lows: Gilead Sciences (NASDAQ:GILD) Vs The Rest Of The Therapeutics Stocks

April 12, 2026

Looking back on therapeutics stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Gilead Sciences (NASDAQ:GILD) and its peers....

Via StockStory

Topics Artificial Intelligence

Gilead Expands Partnership With Tempus AI To Power Cancer Discoveries ↗

April 10, 2026

Tempus AI (TEM) shares up 3.6% on expanded Gilead oncology deal. Explore technical support levels, ALERT trial success, and analyst ratings.

Via Benzinga

Topics Artificial Intelligence

Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis

April 09, 2026

In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total...

Via MarketMinute

Topics Bonds

Gilead Expands Tempus AI Partnership To Boost Oncology Pipeline ↗

April 09, 2026

Gilead expands Tempus AI deal and licenses Kymera's KT-200, advancing oncology pipeline with data, analytics and drug development.

Via Benzinga

Topics Artificial Intelligence

GILEAD SCIENCES INC (NASDAQ:GILD): A Durable Dividend Stock for Income Investors ↗

March 10, 2026

Via Chartmill

Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal ↗

April 07, 2026

Gilead shares dip after $3.15 billion Tubulis deal adds ADC asset, as multiple acquisitions reshape oncology and autoimmune pipeline outlook.

Via Benzinga

Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

April 07, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Extends Tender Offer for Arcellx as Biotech M&A Sentiment Faces a Reality Check

April 06, 2026

Gilead Sciences (NASDAQ: GILD) announced a strategic extension of its tender offer to acquire cell therapy innovator Arcellx (NASDAQ: ACLX) on April 1, 2026. Originally scheduled to expire on April 2,...

Via MarketMinute

Gilead Extends Tender Offer to Acquire Arcellx

April 01, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences's Q1 2026 Earnings: What to Expect

April 01, 2026

Gilead Sciences is expected to announce its first-quarter results soon, and analysts are projecting single-digit EPS growth.

Via Barchart.com

Topics ETFs Workforce

Gilead Sciences Acquires Ouro Medicines for $2.2 Billion to Lead 'Immune Reset' Revolution

March 31, 2026

In a move that signals a decisive shift in the treatment of chronic autoimmune conditions, Gilead Sciences (NASDAQ:GILD) announced on March 23, 2026, its definitive agreement to acquire Ouro Medicines...

Via MarketMinute

Options Action: Naked Put Trade Ideas for March 31

March 31, 2026

With market volatility on the rise, put premiums are highly elevated, so it’s a good time to check in on Barchart’s Naked Put Screener.

Via Barchart.com

Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge ↗

March 30, 2026

This clinical-stage biotech focused on targeted cancer therapies reported a notable insider sale.

Via The Motley Fool

Topics Regulatory Compliance

$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗

March 30, 2026

Via Benzinga

Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion Acquisition ↗

March 24, 2026

Gilead to acquire Ouro Medicines for $1.675 billion, explores Galapagos collaboration, outlines cost-sharing and royalty terms.

Via Benzinga

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

March 23, 2026

From Gilead Sciences, Inc.

Via Business Wire

The Record-Breaking M&A Renaissance of 2026: Why Deal Values are Soaring as Volume Dips

March 19, 2026

As the first quarter of 2026 draws to a close, the U.S. financial landscape has been reshaped by a staggering surge in corporate consolidation. Total deal value for the quarter reached a historic...

Via MarketMinute

Topics Artificial Intelligence Economy Workforce

3 Reasons to Avoid GILD and 1 Stock to Buy Instead

March 18, 2026

Since March 2021, the S&P 500 has delivered a total return of 70.9%. But one standout stock has nearly doubled the market - over the past five years, Gilead ...

Via StockStory

Topics Stocks

This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗

March 16, 2026

Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.

Via The Motley Fool

Topics Regulatory Compliance

Movers and shakers in today's after-hours session for S&P500 stocks? ↗

March 16, 2026

Via Chartmill

2 Mega-Cap Nasdaq Stocks with Unusual Options Activity: What to Watch

March 16, 2026

By taking advantage of Barchart’s scanning tools and doing a small bit of legwork, investors can gain powerful insights.

Via Barchart.com

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗

March 11, 2026

Via Benzinga

2 Recession-Resistant Dividend Stocks to Buy Now ↗

March 11, 2026

It's important to always be prepared.

Via The Motley Fool

Topics Economy

What 16 Analyst Ratings Have To Say About Gilead Sciences ↗

March 10, 2026

Via Benzinga

3 Blue-Chip Stocks Built for a Rotating Market ↗

March 08, 2026

Via MarketBeat

These 3 Cash Flow Machines Provide Stability in Uncertain Markets ↗

March 06, 2026

Via MarketBeat

Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing ↗

March 04, 2026

This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline.

Via The Motley Fool

Topics Regulatory Compliance

Compugen (CGEN) Q4 2025 Earnings Call Transcript ↗

March 02, 2026

Compugen (CGEN) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia

March 02, 2026

From Gilead Sciences, Inc.

Via Business Wire

Arcellx President Sells $10 Million Worth of Shares After Acquisition Announcement ↗

March 02, 2026

Arcellx shares have jumped 75% in 2026, but that's because the stock will soon be off the market.

Via The Motley Fool

Topics Regulatory Compliance

< Previous 1 2 3 4 5 6 7 8 9

...

72 73 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.